Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Targeting the Src N-Terminal Regulatory Element in Cancer

News

June 9, 2023
PRESS RELEASE: On May 19, 2023, Oncotarget published a new research perspective: “Targeting the Src N-terminal regulatory element in cancer.” continue reading »

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

News

June 7, 2023
PRESS RELEASE: On May 26, 2023, a new research paper was published in Oncotarget, entitled, “Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC).” continue reading »

BORIS Gene Mutation and Expression: Link to Breast Cancer Progression

News

June 5, 2023
PRESS RELEASE: On May 26, 2023, a new research paper was published in Oncotarget, entitled, “Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.” continue reading »

Deconstructing the Role of MALAT1 in MAPK-Signaling in Melanoma

News

May 30, 2023
PRESS RELEASE: On May 26, 2023, a new research paper was published in Oncotarget, entitled, “Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.” continue reading »

Can the Creatine Shuttle be Targeted to Fight Colorectal Cancer?

Oncotarget

May 25, 2023
In a new study, researchers investigated the creatine shuttle pathway as a potential therapeutic target in colorectal cancer cells. continue reading »